Pharmafile Logo
Pharmafocus logo
Advanced Search

sofosbuvir

Showing 13 posts of 28 posts found.

Sovaldi image

NICE approves Sovaldi

January 16, 2015
Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, pharma, sofosbuvir, sovaldi

NICE has recommended Sovaldi in final draft guidance and extended its scope, despite concerns over the price of the blockbuster …

News
Sovaldi image

Gilead sued over Sovaldi price

December 15, 2014
Sales and Marketing BMS, Gilead, NICE, harvoni, hep C, septa, sofosbuvir, sovaldi

A payer is suing Gilead over the price of its hep-c drug Sovaldi in the US after spending $2.4 million …

News
Harvoni image

Gilead gets Harvoni boost for Europe

November 20, 2014
Sales and Marketing EU, Gilead, HCV, harvoni, hepc, ledipasvir, sofosbuvir, svaldi

Gilead Sciences’ new hepatitis C (HCV) tablet Harvoni has been approved across the European Union to treat the majority of …

News
Sovaldi image

Sovaldi misses estimates but still makes history

October 29, 2014
Research and Development, Sales and Marketing FDA, Gilead, harvoni, hep C, sofosbuvir, sovaldi

The trajectory of Gilead’s new hep C pill Sovaldi has slowed but the drug is still on course to break …

News
Sovaldi image

Gilead allows generic prices for Sovaldi

September 16, 2014
Manufacturing and Production, Sales and Marketing Gilead, hep C, hepatitis C, sofosbuvir, sovaldi

Gilead will allow Indian generic drug firms to make cheap copies of its new hepatitis C pill Sovaldi in an …

News
gilead_-sciences

NICE rejection looms for Sovaldi

June 16, 2014
Sales and Marketing Gilead, NHS, NICE, SMC, hep C, sofosbuvir, sovaldi

In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi …

News
Sovaldi image

Sovaldi hurdles first drug pricing barrier

June 10, 2014
Sales and Marketing Gilead, SMC, Scotland, hep C, sofosbuvir, sovaldi

Scotland’s NHS will pay for Gilead’s new hepatitis C pill Sovaldi despite rising concern over its high cost. The Scottish …

News
Biocon image

Novartis sues Biocon

April 4, 2014
Sales and Marketing Biocon, Galvus, Gilead, Herceptin, Novartis, sofosbuvir

India’s status as a battleground for patent issues has been reinforced with the news that Novartis is suing Biocon over …

News
Sovaldi image

Gilead to allow cheaper generics of new hep C drug

February 6, 2014
Manufacturing and Production, Sales and Marketing Gilead, India, generics, hep C, s&m, sofosbuvir, sovaldi

Gilead has announced the unusual step of allowing its new and highly expensive hepatitis C pill to be sold as …

News

Europe nod for Gilead HCV pill

January 20, 2014
Sales and Marketing FDA, Gilead, HCV, hep C, sofosbuvir, sovaldi

Gilead Sciences’ once-daily, oral hepatitis C treatment Sovaldi has been given the green light by the European Commission, just a …

News
sovaldi image

Gilead’s $1,000 per day Hep C drug approved

December 9, 2013
Sales and Marketing FDA, Gilead, hepc, sofosbuvir, sovaldi

Gilead’s Sovaldi has gained FDA approval as a potential cure for hepatitis C after the US regulator sped up its …

News
Gilead image

Gilead runs into India patent trouble

November 26, 2013
Sales and Marketing Gilead, MSF, hepc, sofosbuvir, sovaldi

Gilead Sciences has run into heavy traffic in India as campaigners attempt to block the company’s patent there on new …

News
Gilead image

‘Game-changing’ hep C pill gets FDA panel nod

October 29, 2013
Sales and Marketing FDA, Gilead, hep C, sofosbuvir

Gilead Science’s investigational hepatitis C drug sofosbuvir is one step closer to approval in the US after an FDA advisory …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025